General information on active substances
Sofosbuvir and Velpatasvir are active substances developed and synthesized several years ago that have a targeted effect on the hepatitis C virus and are actively used in the treatment of the chronic form of the course of this infection. An important point - both components are taken exclusively in a complex and never separately. Only in this case, an infected person can get a positive result from undergoing therapy. According to data obtained during experimental treatment with the participation of volunteers and based on an analysis of the subsequent application of the integrated regimen in practice, in 99% of cases, patients receive a stable virological response and become completely healthy by the end of treatment. You can Check Sofosbuvir Velpatasvir price in India.
All of the above has influenced the fact that both substances included in this scheme are produced as part of complex preparations. Velpatasvir in the form of a single drug is not on sale. The first on the market was the original Epclusa medicine, released and patented by the large American pharmaceutical corporation Gilead Sciences Ireland UC. It has been approved by the FDA since 2016, June 28th. Unfortunately, this medicine is not available to a wide audience of patients, since its cost is too high even for average residents of the United States, not to mention those countries where the standard of living is much lower. Due to the price factor, after a short period of time, Gilead granted a license to several Indian pharmaceutical companies for the production of analog antiviral agents according to the original formula. They have the same properties and characteristics, up to the effect, but in this case, the pricing policy is ten times lower. Therefore, today almost all people who need it can receive high-quality treatment. You can buy Generic Epclusa 98times Cheaper than Orignal Epclusa
Sofosbuvir and Velpatasvir according to the instructions for use are active metabolites, inhibitors of RNA polymerase of viral proteins. The first substance inhibits the NS5B nucleotide, the second - the NS5A complex. As a result of their simultaneous influence on the pathogen, its replication function (reproduction) is violated. That is, the virus cannot reproduce virions, respectively, they, in turn, do not spread through the blood through the liver and do not affect healthy hepatocytes (liver cells). This leads to the gradual death of the virus and its complete removal from the body of a sick person to the end of therapy.
According to the instructions for the use of Epclusa Cost, they are absorbed in the gastrointestinal tract almost in the first minutes of ingestion. Within fifteen minutes, the main components are activated and begin to interact with the RNA of the virus, almost immediately exerting an inhibitory effect on it. The largest amount of Sofosbuvir in plasma is contained thirty to ninety minutes after ingestion, Velpatasvira in a few hours.
Indications:
In practice, doctors prescribe medication based on Sofosbuvir and Velpatasvir according to the instructions in India, namely, if the patient has a chronic form of hepatitis C of any of the six genotypes. A universal drug has several direct indications for use in treatment, which include:
- an established diagnosis of HCV, in the absence of any complications and concomitant infectious diseases;
- chronic form of hepatitis C, in the presence of decompensated and compensated cirrhosis of the liver;
- first-time treatment of viral hepatitis C;
- repeated treatment, if for the first time, during treatment with other medicines, a person did not get a positive result for any reason.
Sofosbuvir 400 mg / velpatasvir 100 mg is the daily dose needed to treat virologic pathology.
Contraindications
Throughout the entire time, the mild effect of an innovative medication on the patient’s body has been proven more than once, since its main effect is directed exclusively to the pathogen. Nevertheless, the original instructions for the drug clearly indicate a small list of situations when taking it is contraindicated:
- Hypersensitivity of an infected person to one or more elements that are part of a combination drug, due to the fact that a serious allergic reaction of the body can be caused, up to anaphylactic shock and death.
- During pregnancy, this medication is not prescribed, since the properties of Sofosbuvir and Velpatasvir with respect to their effect on the intrauterine development of the fetus have not been studied.
- During the period of breastfeeding, it is contraindicated to carry out treatment with this medicine, since the influence of the main active elements on the body of infants and their further development is unknown.
- Provided that the patient has not yet reached the age of eighteen, it is recommended not to start the therapeutic course until he reaches adulthood. Children and adolescents did not participate in the experimental treatment, therefore, how the combined agent will affect their condition remains unknown.
In all of the above cases, it is not known how sofosbuvir plus velpatasvir will affect the body, so do not ignore these contraindications.
Buy Generic Epclusa Brands in India
Myhep All is a combination of fixed doses of these two most commonly used antiviral drugs. Sofosbuvir and Velpatasvir are direct-acting antiviral agents that are involved in the treatment of chronic hepatitis C virus infections. Sofosbuvir is usually combined with another antiviral agent to exert pronounced effects. Myhep-All is an FDA-approved product used in chronic HCV disease. Myhep-All should be used for hepatitis C virus infections associated with genotype I, II, III, IV, V or VI. Sofosbuvir is an NS5B protein inhibitor, a protein necessary for the production of the virus. Sofosbuvir is a prodrug form that turns into the active uridine-triphosphate form, which is necessary for antiviral activity. This dynamic active fragment is inserted into HCV RNA using NS5B polymerase and acts as a chain eliminator. Velpatasvir pharmacologically acts as an NS5A inhibitor; this protein is essential for the production of HCV virus. Velpatasvir involves its actions in the production of viruses.
Velpanat Natco Pharma is a manufacturer from India who creates a truly effective and reliable product under a white license, which in its properties is in no way inferior to the preparation of Epclusa. The active active ingredients of these medicines are completely identical: Sofosbuvir and Velpatasvir. Both drugs give almost one hundred percent result (up to 98% of cases of cure)! Velpanat (Velpanat), as well as Epclusa (Epclusa) has all the necessary certificates and documents.The only difference between the two drugs is the price. And if not everyone can buy Epclusa (Epclus), then to defeat a terrible disease with the help of Velpanat (Velpanat) is accessible to everyone.
Hetero, an Indian pharmaceutical brand, is one of the leading manufacturers of antiviral generics. All company products are produced on the basis of a licensed formula, the manufacturer carefully monitors the quality and compliance of the main and auxiliary components with WHO standards. As a result, Velasof, developed for the treatment of hepatitis C of all currently identified virus genotypes, shows a high degree of safety (minimum side effects). Statistics show that in 95% of cases, patients even with complicated forms of HCV get rid of the “gentle killer” without the risk of reactivation.